Kymera Posts $1.32 Per-Share Q3 Loss as KT-621 Data Looms
KYMR has more than doubled off its 52-week low of $55.66.
Summary
Kymera reported a third-quarter loss of $1.32 per share, its first quarterly update since the Q2 print that showed $65 million in revenue and $1.5 billion in cash with runway into 2029. The net loss widened as research and development costs rose, though the headline carries no revenue figure, so the size of the loss relative to the prior quarter's $61.2 million net loss is not yet clear from this line alone. The balance sheet is the key variable: with a $500 million at-the-market program already in place, the cash position and any change in share count will determine how much dilution the KT-621 program requires. The company also reported positive results from the KT-579 Phase 1 healthy volunteer trial. Topline Phase 2b data for KT-621 in atopic dermatitis is expected by year-end 2026, the event that will actually reprice the stock.
At the time of this announcement, KYMR was trading at $122.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.2B. The 52-week trading range was $55.66 to $130.05. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.